<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1292">
  <stage>Registered</stage>
  <submitdate>18/05/2006</submitdate>
  <approvaldate>26/05/2006</approvaldate>
  <actrnumber>ACTRN12606000197538</actrnumber>
  <trial_identification>
    <studytitle>Selenium, CAD, inflammation and endothelial function</studytitle>
    <scientifictitle>Do selenium supplements improve inflammation and endothelial function markers in patients with coronary artery stenosis in Otago?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Coronary artery stenosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>oral selenomethionine supplements 100 mcg daily. duration of supplementation is 3 months.</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Biochemical endothelial function markers Icam and Vcam</outcome>
      <timepoint>At 3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Glutathione peroxidase activity, peroxide and paraoxonase levels.</outcome>
      <timepoint>At 3 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Coronary artery stenosis at least 30% on any of the three major vessels.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>CABG after angiography, myocardial infarct in previous 48Hrsalready taking seleniumhemodynamically significant valvular diseasesurgery or trauma within the past month.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed opaque envelopes</concealment>
    <sequence>Blocks, simple randomization by using a computer generated sequence</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/06/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Otago Medical Research Foundation</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Otago School of Medicine Dean's bequest fund</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Southland Medical Research Foundation.</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients undergoing cardiac catheterization in Dunedin will be informed about the research project. Patients who enter the study will receive either selenium or placebo (dummy tablet) for 3 months. Because this study is "double blind", neither the researchers nor the patients will know who is taking selenium and who is taking placebo until the end of the study. Blood samples will be taken at the start of the study and at three months. We will be able to tell whether selenium improves markers of inflammation and endothelial function in patients with coronary disease by measuring and comparing these markers on the two successive samples for the two groups. This is important because inflammation and endothelial function are linked to progression of heart disease and because there is good evidence that selenium may help reduce inflammation</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Lower South Regional Ethics Committee- Dunedin Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>17/05/2006</ethicapprovaldate>
      <hrec>LRS/06/05/021</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Nathalie van Havre</name>
      <address>Southland Medical Foundation
W and G S Dick Senior Research Fellow
Cardiology Section
Department of Medical and Surgical Sciences
University of Otago
PO Box 913
Dunedin</address>
      <phone>+64 2 76627221</phone>
      <fax>+61 3 4747641</fax>
      <email>nathalie.vanhavre@stonebow.otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Nathalie van Havre</name>
      <address>Southland Medical Foundation
W and G S Dick Senior Research Fellow
Cardiology Section
Department of Medical and Surgical Sciences
University of Otago
PO Box 913
Dunedin
Tel: 64-3-474-0999 ext 8514</address>
      <phone>+64 2 76627221</phone>
      <fax>+61 3 4747641</fax>
      <email>nathalie.vanhavre@stonebow.otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>